Active Cancer NIHR-supported project Digestion, Kidneys & Other Organs
CRIMSON: A multicentre randomised, sham-controlled (and active controlledin the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy.
About this grant
This summary is based on the grant title only — the full abstract was not available.
No substantive source abstract was published for this research project funded by NIHR.
Researchers
Simona Eposti (Principal Investigator)
Related Research
Grants with similar aims, by meaning.
A multicentre randomised, sham-controlled (and active controlledin the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy.
A First-in Human trial to study safety and tolerability of single rising intravitreal dOses (open label, non-randomized, uncontrolled) and in addition the early biological response of multiple rising intravitReal doses (single-masked, raNdomized, sham-controlled) of BI 764524 in panretinaL photocoagulation (PRP) treated proLiferative diabetic retinopathy (PDR) patients with diabetic macular ischemia (DMI) – the HORNBILL Study
A First-in Human trial to study safety and tolerability of single rising intravitreal doses (open label, non-randomized, uncontrolled) and in addition the early biological response of multiple intravitreal doses (single-masked, randomized, shamcontrolled) of BI 765128 in panretinalphotocoagulation (PRP) treated proliferative diabetic retinopathy (PDR) patients with diabetic macular ischemia (DMI)
A First-in Human trial to study safety and tolerability of single rising intravitreal dOses (open label, non-randomized, uncontrolled) and in addition the early biological response of multiple rising intravitReal doses (single-masked, raNdomized, sham-controlled) of BI 764524 in panretinaL photocoagulation (PRP) treated proLiferative diabetic retinopathy (PDR) patients with diabetic macular ischemia (DMI) û the HORNBILL Study
A phase ii, multicenter, randomized, double masked, active comparatorcontrolled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of ro7200220 administered intravitreally in patients with diabetic macular edema
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know